News
- NovaTarg is awarded an SBIR Phase 2b grant to support the early development of NT1195 for Type 2 Diabetes (T2D) in patients with kidney disease. January 8, 2019
- NovaTarg is approved for a $250,000 loan from the NC Biotech Center March 8, 2017
- NT1195 is selected as a drug candidate for the treatment of Type 2 Diabetes in patients with impaired renal function. IND-enabling studies begin. February 8, 2017
- NovaTarg has received $3.2 million in SBIR grant funding to further its discovery of tissue selective AMPK activators. September 8, 2015
- Dr Victoria Bae-Jump, MD, PhD, (UNC) has received a Collaborative Funding Grant (CFG) from the North Carolina Biotech Center (NCBC) to support research on NovaTarg’s AMPK activators as potential treatments for ovarian cancer. June 9, 2015